Share this

KN 426 SITC

References:

  1. Keytruda Summary of Product Characteristics.
  2. Kantar Health. Treatment Architecture: Renal Cell Carcinoma.Cancer MPact®. EU5. 2020;1–89.

AE-RCC-00004 | Exp : 06 JUN 2024
AE-RCC-00003 | Exp : 06 JUN 2024
QA-RCC-00001 | Exp : 06 JUN 2024

References:

  1. Keytruda Summary of Product Characteristics.
  2. Rini BI, Plimack ER, Stus V, et al; for the KEYNOTE-426 investigators. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019; 380 (12): 1116–1127.

AE-RCC-00004 | Exp : 06 JUN 2024
AE-RCC-00003 | Exp : 06 JUN 2024
QA-RCC-00001 | Exp : 06 JUN 2024

References:

  1. Keytruda Summary of Product Characteristics.
  2. ASCO 2023: Pembrolizumab (Pembro) plus axitinib (AXI) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccrcc): Results of 5 years follow-up of keynote-426 (no date) UroToday. Available at: https://www.urotoday.com/conference-highlights/asco-2023/asco-2023-kidney-cancer/144965-asco-2023-pembrolizumab-axitinib-versus-sunitinib-as-first-line-therapy-for-advanced-clear-cell-rcc-5-year-analysis-of-keynote-426.html (Accessed: 20 August 2023).

AE-RCC-00004 | Exp : 06 JUN 2024
AE-RCC-00003 | Exp : 06 JUN 2024
QA-RCC-00001 | Exp : 06 JUN 2024

References:

  1. Keytruda Summary of Product Characteristics.
  2. Inlyta [SmPC]. Belgium: Pfizer Europe MA EEIG; 2021

AE-RCC-00004 | Exp : 06 JUN 2024
AE-RCC-00003 | Exp : 06 JUN 2024
QA-RCC-00001 | Exp : 06 JUN 2024

References:

  1. Keytruda Summary of Product Characteristics.
  2. Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer, 12(4),252–264.
    https://doi.org/10.1038/nrc3239.
  3. Inlyta [SmPC]. Belgium: Pfizer Europe MA EEIG; 2021

AE-RCC-00004 | Exp : 06 JUN 2024
AE-RCC-00003 | Exp : 06 JUN 2024
QA-RCC-00001 | Exp : 06 JUN 2024

References:

  1. Keytruda Summary of Product Characteristics.
  2. Rini BI, Battle D, Figlin RA, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). J Immunother Cancer. 2019;7(1):354.

AE-RCC-00004 | Exp : 06 JUN 2024
AE-RCC-00003 | Exp : 06 JUN 2024
QA-RCC-00001 | Exp : 06 JUN 2024